Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

December 07, 2007

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue.

Check this box

if no longer

subject to

Section 16.

Form 4 or

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * **BOGER JOSHUA S**

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol VERTEX PHARMACEUTICALS

(Check all applicable)

INC / MA [VRTX]

3. Date of Earliest Transaction

X Director 10% Owner X_ Officer (give title Other (specify below)

(Month/Day/Year) 12/06/2007

President & CEO

PHARMACEUTICALS INCORPORATED, 130 WAVERLY

(Street)

(First)

(Middle)

STREET

(Last)

C/O VERTEX

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

CAMBRIDGE, MA 02139

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
G			Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	12/06/2007		M	17,500	A	\$ 13.67	1,113,342	D		
Common Stock	12/06/2007		S(1)(2)	700	D	\$ 26.01	1,112,642	D		
Common Stock	12/06/2007		S(1)(3)	1,900	D	\$ 25.95	1,110,742	D		
Common Stock	12/06/2007		S(1)(4)	1,000	D	\$ 25.84	1,109,742	D		

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	12/06/2007	S(1)(5)	1,300	D	\$ 25.75	1,108,442	D	
Common Stock	12/06/2007	S(1)(6)	2,500	D	\$ 25.63	1,105,942	D	
Common Stock	12/06/2007	S(1)(7)	2,800	D	\$ 25.53	1,103,142	D	
Common Stock	12/06/2007	S(1)(8)	4,400	D	\$ 25.47	1,098,742	D	
Common Stock	12/06/2007	S(1)(9)	900	D	\$ 25.34	1,097,842	D	
Common Stock	12/06/2007	S(1)(10)	800	D	\$ 25.27	1,097,042	D	
Common Stock	12/06/2007	S(1)(11)	1,200	D	\$ 25.14	1,095,842	D	
Common Stock						12,445	I	401(k)
Common Stock						207,500	I	Shares in trust (13)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number of		6. Date Exer	6. Date Exercisable and		7. Title and Amount of	
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	onDerivative	Expiration D	Expiration Date		Underlying Securities	
Security	or Exercise		any	Code Securities		(Month/Day	(Month/Day/Year)		4)	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8) Acquired (A)						
	Derivative			or Disposed of		of				
	Security			(D)						
	•				(Instr. 3, 4,					
					and 5)					
						ъ.	E		Amount	
						Date	Expiration	Title	or	
				C 1 W	(A) (D)	Exercisable	Date		Number	
				Code V	(A) (D)				of Shares	
Stock Option	\$ 13.67	12/06/2007		M	17,50	(12)	12/11/2007	Common Stock	17,500	

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners 2

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Director 10% Owner Officer Other

BOGER JOSHUA S C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139

X President & CEO

Signatures

Valerie L. Andrews, Attorney-In-Fact

12/07/2007

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- (2) Aggregate sales made at prices between \$26.00 and \$26.05.
- (3) Aggregate sales made at prices between \$25.90 and \$25.99.
- (4) Aggregate sales made at prices between \$25.81 and \$25.89.
- (5) Aggregate sales made at prices between \$25.71 and \$25.79.
- (6) Aggregate sales made at prices between \$25.60 and \$25.67.
- (7) Aggregate sales made at prices between \$25.50 and \$25.58.
- (8) Aggregate sales made at prices between \$25.40 and \$25.49.
- (9) Aggregate sales made at prices between \$25.31 and \$25.39.
- (10) Aggregate sales made at prices between \$25.22 and \$25.29.
- (11) Aggregate sales made at prices between \$25.10 and \$25.19.
- (12) Fully vested.
- (13) Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3